These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8172713)

  • 1. Current clinical studies with a new nonsteroidal antiandrogen, Casodex.
    Kaisary AV
    Prostate Suppl; 1994; 5():27-33. PubMed ID: 8172713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of Casodex (bicalutamide): preclinical studies.
    Furr BJ
    Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical progress with a new antiandrogen, Casodex (bicalutamide).
    Blackledge GR
    Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
    Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group.
    Kaisary AV; Tyrrell CJ; Beacock C; Lunglmayr G; Debruyne F
    Eur Urol; 1995; 28(3):215-22. PubMed ID: 8536775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators.
    Iversen P
    Eur Urol; 1994; 26 Suppl 1():5-9. PubMed ID: 7737258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
    Tyrrell CJ; Kaisary AV; Iversen P; Anderson JB; Baert L; Tammela T; Chamberlain M; Webster A; Blackledge G
    Eur Urol; 1998; 33(5):447-56. PubMed ID: 9643663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
    Tyrrell CJ; Denis L; Newling D; Soloway M; Channer K; Cockshott ID
    Eur Urol; 1998; 33(1):39-53. PubMed ID: 9471040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.
    Blackledge GR; Cockshott ID; Furr BJ
    Eur Urol; 1997; 31 Suppl 2():30-9. PubMed ID: 9074908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of prostate-specific antigen as a predictor of outcome in prostate cancer.
    Blackledge GR; Lowery K
    Prostate Suppl; 1994; 5():34-8. PubMed ID: 7513530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
    McLeod DG; Schellhammer PF; Vogelzang NJ; Soloway MS; Sharifi R; Block NL; Venner PM; Patterson AL; Sarosdy MF; Kelley RP; Kolvenbag GJ
    Prostate; 1999 Sep; 40(4):218-24. PubMed ID: 10420149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.
    Tyrrell CJ
    Eur Urol; 1994; 26 Suppl 1():15-9. PubMed ID: 7537664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.
    Kolvenbag GJ; Blackledge GR; Gotting-Smith K
    Prostate; 1998 Jan; 34(1):61-72. PubMed ID: 9428389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
    Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
    Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
    Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bicalutamide dosages used in the treatment of prostate cancer.
    Kolvenbag GJ; Nash A
    Prostate; 1999 Apr; 39(1):47-53. PubMed ID: 10221266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group.
    Iversen P; Tveter K; Varenhorst E
    Scand J Urol Nephrol; 1996 Apr; 30(2):93-8. PubMed ID: 8738052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.
    Verhelst J; Denis L; Van Vliet P; Van Poppel H; Braeckman J; Van Cangh P; Mattelaer J; D'Hulster D; Mahler C
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):525-30. PubMed ID: 7525125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer.
    Tyrrell CJ
    Prostate Suppl; 1992; 4():97-104. PubMed ID: 1574464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
    Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Baert L; Tammela T; Chamberlain M; Carroll K; Gotting-Smith K; Blackledge GR
    Urology; 1998 Mar; 51(3):389-96. PubMed ID: 9510340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.